{"nctId":"NCT01665144","briefTitle":"Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)","startDateStruct":{"date":"2012-12-20","type":"ACTUAL"},"conditions":["Secondary Progressive Multiple Sclerosis"],"count":1651,"armGroups":[{"label":"Siponimod (BAF312)","type":"EXPERIMENTAL","interventionNames":["Drug: BAF312"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BAF312","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Prior history of relapsing remitting MS\n* SPMS defined as progressive increase of disability over at least 6 months\n* EDSS score of 3.0 to 6.5\n* No relapse of corticosteroid treatment within 3 months\n\nExclusion Criteria:\n\n* Women of child bearing potential must use reliable forms of contraception.\n* Diagnosis of Macular edema during screening period\n* Any medically unstable condition determined by investigator.\n* Unable to undergo MRI scans\n* Hypersensitivity to any study drugs or drugs of similar class","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)","description":"The EDSS uses an ordinal scale to assess neurologic impairment in MS based on a neurological examination. Scores in each of 7 functional systems (Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \\& Bladder, and Cerebral) and an ambulation score were combined to determine the EDSS steps, ranging from 0 (normal) to 10 (death due to MS). 3-month confirmed disability progression is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5 sustained for at least 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 3-month Confirmed Worsening in T25W of at Least 20% From Baseline","description":"The Timed 25-Foot Walk Test (T25W) measured the time, in seconds, to walk 25 feet (7.62 meters).\n\nA 3-month confirmed worsening of at least 20% from baseline in the T25W was defined as an increase from baseline sustained for at least 3 months.\n\nThis outcome measure was analyzed using a Cox proportional hazards model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in T2 Lesion Volume","description":"Magnetic resonance imaging (MRI) scans of the brain were performed every 12 months. MRI evaluation during the Core Part included the total volume of T2 lesions. Each MRI scan was reviewed by a local neurologist and by a central blinded MRI reading center.\n\nThe change from baseline in T2 lesion volume was analyzed using a mixed model for repeated measures (MMRM) with visit as a categorical factor and an unstructured covariance matrix and with adjustment for baseline covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204.9","spread":"67.47"},{"groupId":"OG001","value":"818.0","spread":"87.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.9","spread":"73.90"},{"groupId":"OG001","value":"940.4","spread":"97.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183.9","spread":"66.33"},{"groupId":"OG001","value":"879.2","spread":"85.43"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 6-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)","description":"The EDSS uses an ordinal scale to assess neurologic impairment in multiple sclerosis (MS) based on a neurological examination. Scores in each of 7 functional systems (Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \\& Bladder, and Cerebral) and an ambulation score were combined to determine the EDSS steps, ranging from 0 (normal) to 10 (death due to MS).\n\n6-month confirmed disability progression is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5 sustained for at least 6 months.\n\nThis outcome measure was analyzed using a Cox proportional hazards model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":null},{"groupId":"OG001","value":"25.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate (ARR) for Confirmed Relapses","description":"Multiple sclerosis (MS) relapse was defined as appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. Additionally, the abnormality had to be present for at least 24 hours and occur in the absence of fever (\\<37.5°C) or known infection.\n\nA confirmed MS relapse was defined as accompanied by a clinically-relevant change in the EDSS, as defined in the study protocol, performed by the Independent EDSS Rater.\n\nARR was defined as the average number of confirmed relapses per year. ARR was analyzed using a negative binomial regression model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.071","spread":null},{"groupId":"OG001","value":"0.160","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With First Relapse Events as Measured by Time to First Confirmed Relapse","description":"Multiple sclerosis (MS) relapse was defined as appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. Additionally, the abnormality had to be present for at least 24 hours and occur in the absence of fever (\\<37.5°C) or known infection.\n\nA confirmed MS relapse was defined as accompanied by a clinically-relevant change in the EDSS, as defined in the study protocol, performed by the Independent EDSS Rater.\n\nTime to first relapse was defined as the time from Day 1 until the start of relapse symptoms. Patients without relapse were censored at the latest known date to be at risk.\n\nThis outcome measure was analyzed using a Cox proportional hazards model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Relapse (Confirmed Relapse and Any Relapse)","description":"Multiple sclerosis (MS) relapse was defined as appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. Additionally, the abnormality had to be present for at least 24 hours and occur in the absence of fever (\\<37.5°C) or known infection.\n\nA confirmed MS relapse was defined as accompanied by a clinically-relevant change in the EDSS, as defined in the study protocol, performed by the Independent EDSS Rater.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MSWS-12 Converted Score","description":"The Multiple Sclerosis Walking Scale (MSWS-12) version 2 is a patient-rated measure of walking consisting of 12 items. Walking limitations were reported by the patients using categories, generating a total transformed score ranging from 0-100. Higher scores reflected greater impairment.\n\nThe change from baseline in MSWS-12 converted score was analyzed using a repeated measures model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.678"},{"groupId":"OG001","value":"3.36","spread":"0.908"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.16","spread":"0.848"},{"groupId":"OG001","value":"5.38","spread":"1.167"}]}]}]},{"type":"SECONDARY","title":"Number of T1 Gd-enhancing Lesions Per Patient Per Scan","description":"Magnetic resonance imaging (MRI) scans of the brain were performed every 12 months. MRI evaluation during the Core Part included the number of T1 gadolinium (Gd)-enhancing lesions. Each MRI scan was reviewed by a local neurologist and by a central blinded MRI reading center.\n\nThe number of T1 Gd-enhancing lesions per patient per scan was analyzed using a negative binomial regression model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.080","spread":null},{"groupId":"OG001","value":"0.640","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.074","spread":null},{"groupId":"OG001","value":"0.418","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New or Enlarging T2 Lesions Per Patient Per Year","description":"Magnetic resonance imaging (MRI) scans of the brain were performed every 12 months. MRI evaluation during the Core Part included the number of new or enlarging T2 lesions. Each MRI scan was reviewed by a local neurologist and by a central blinded MRI reading center.\n\nThe number of new or enlarging T2 lesions compared to previous scan was analyzed using a repeated measures negative binomial regression model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.003","spread":null},{"groupId":"OG001","value":"3.776","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.489","spread":null},{"groupId":"OG001","value":"3.437","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Brain Volume Change (PBVC) Relative to Baseline","description":"Magnetic resonance imaging (MRI) scans of the brain were performed every 12 months. MRI evaluation during the Core Part included the percentage change in brain volume. Each MRI scan was reviewed by a local neurologist and by a central blinded MRI reading center.\n\nPBVC relative to baseline was analyzed using a repeated measures model (for normally distributed data) with visit as a categorical factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.283","spread":"0.0264"},{"groupId":"OG001","value":"-0.458","spread":"0.0341"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.711","spread":"0.0356"},{"groupId":"OG001","value":"-0.839","spread":"0.0476"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of SPMS Patients With/Without Superimposed Relapses","description":"The Expanded Disability Status Scale (EDSS) assesses neurologic impairment in multiple sclerosis (MS). EDSS scale ranges from 0 (normal) to 10 (death due to MS). Confirmed disability is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.\n\nThe definition of 3-month confirmed disability progression (CDP) was an increase from baseline in EDSS as defined before sustained for at least 3 months.\n\nThe following secondary progressive multiple sclerosis (SPMS) groups were defined for the analysis of this endpoint:\n\n* Without superimposed relapses in the 2 years prior to study start (baseline definition)\n* With superimposed relapses in the 2 years prior to study start (baseline definition)\n* Without superimposed relapses during the Core Part of study (post-treatment)\n* With superimposed relapses during the Core Part of study (post-treatment) Data was analyzed using a Cox proportional hazard model","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"237","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of Rapidly and Not Rapidly Evolving Patients","description":"The Expanded Disability Status Scale (EDSS) assesses neurologic impairment in multiple sclerosis (MS). EDSS scale ranges from 0 (normal) to 10 (death due to MS). Confirmed disability is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.\n\nThe definition of 3-month confirmed disability progression (CDP) was an increase from baseline in EDSS as defined before sustained for at least 3 months.\n\nRapidly evolving patients are defined as subjects with 1.5 or greater EDSS change in the 2 years prior to or at study start and disability progression in the 2 years prior to study start was not adjudicated.\n\nData was analyzed using a Cox proportional hazard model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 3-month CDP Events as Measured by EDSS in the Subgroup of Patients With and Without Moderate/Severe Disease Course","description":"The Expanded Disability Status Scale (EDSS) assesses neurologic impairment in multiple sclerosis (MS). EDSS scale ranges from 0 (normal) to 10 (death due to MS). Confirmed disability is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.\n\nThe definition of 3-month confirmed disability progression (CDP) was an increase from baseline in EDSS as defined before sustained for at least 3 months.\n\nModerate or severe course of disease is defined as global Multiple Sclerosis Severity Score (MSSS) of 4 or more at baseline.\n\nData was analyzed using a Cox proportional hazard model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":196,"n":1099},"commonTop":["Urinary tract infection","Nasopharyngitis","Fall","Headache","Hypertension"]}}}